May 5, 2015
SNMMI and the American Society of Nuclear Cardiology (ASNC) organized the Cardiovascular Molecular Imaging Think Tank: Devising Strategies to Bridge the Translational Divide, which took place April 16-17 at the ACC Heart House in Washington, DC.
This meeting invited individuals with diverse scientific, clinical, industry and research funding perspectives on the development of cardiovascular (CV) molecular imaging to focus on its translation to the clinic. Attendees included key stakeholders in this process including: (1) experts in the preclinical development of these techniques and clinical CV imaging; (2) leading CV clinical practitioners; (3) individuals with expertise in the development and regulation of new CV pharmaceuticals and devices; and 4) senior NIH staff with an interest in CV molecular imaging. Attendees included, among others, Libero Marzella, MD, representing the Food and Drug Administration, and Denis Buxton, PhD, Narasimhan Danthi, PhD, Christina Liu, PhD, and Antonio Sastre, PhD, representing the National Institutes of Health.
The impetus for this meeting was the presence of the significant translational divide that hinders the exportation of advances in preclinical CV molecular imaging to the clinic. The goal of this meeting was to devise strategies to bridge this divide. To achieve this goal, the meeting focused on identifying gaps in the current practice of CV medicine that may be addressed by existing or emerging molecular imaging tools. Efforts were aimed at devising solutions and recommendations for facilitating clinical translation.
The meeting was organized into short lectures combined with panel discussions followed by breakout sessions on selected topics. The lectures and breakout sessions addressed CV molecular imaging applications in arrhythmias, heart failure and valvular disease, and vascular disease and thrombosis. The discussions within these areas included: (1) industry, regulatory and CMS/reimbursement perspectives; (2) the scope of the clinical problem and strategies to address diagnostic gaps; and (3) potential opportunities linking imaging to clinical action.
A summary of the conclusions and recommendations from the meeting will be published in a white paper later this year.